{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:59:08Z","timestamp":1790229548137,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Solid organ transplant recipients (SOTRs) face frequent advanced cutaneous malignancies, yet data guiding systemic therapy are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses systematic review of immune checkpoint inhibitors (ICIs), talimogene laherparepvec (T-VEC), and Sonic Hedgehog Pathway Inhibitors (HPIs) for locally advanced or metastatic cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma, and basal cell carcinoma in SOTRs, including a novel case from our institution. Outcomes included tumor response, graft rejection, and graft failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 196 SOTRs treated with ICIs (101 cutaneous squamous cell carcinoma, 83 melanoma, 12 Merkel cell carcinoma), the overall response rate (ORR) was 39.3%, and lack of progression occurred in 58.0%. Graft rejection occurred in 36.9% and graft failure in 22.3%. A higher number of baseline immunosuppressive agents decreased odds of rejection (OR 0.55) and failure (OR 0.38). Tacrolimus was associated with reduced tumor response (OR 0.41), whereas mTOR-based regimens and cemiplimab were associated with fewer transplant rejection. T-VEC was reported in 10 SOTRs with an ORR of 90% and no graft rejection or failure. HPIs in six SOTRs with basal cell carcinoma demonstrated ORR of 83% without graft loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>ICIs provide antitumor activity but substantial graft-related risk, while T-VEC and HPIs show high response rates with no reported rejection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005114","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:00:08Z","timestamp":1776369608000},"page":"929-937","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Therapies for the Treatment of Cutaneous Malignancies in Solid Organ Transplant Recipients"],"prefix":"10.1097","volume":"52","author":[{"given":"Akshay","family":"Pulavarty","sequence":"first","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Maas","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archie","family":"Spindler","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Kalyan","sequence":"additional","affiliation":[{"name":"Department of Oncology, New York University School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayoung","family":"Lee","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Stevenson","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Department of Oncology, New York University School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Mehnert","sequence":"additional","affiliation":[{"name":"Department of Oncology, New York University School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Carucci","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maressa C.","family":"Criscito","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"R1-20260924","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2010.11.062","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients","volume":"65","author":"O'Reilly Zwald","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R2-20260924","doi-asserted-by":"crossref","first-page":"dju382","DOI":"10.1093\/jnci\/dju382","article-title":"Risk of merkel cell carcinoma after solid organ transplantation","volume":"107","author":"Clarke","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R3-20260924","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R4-20260924","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R5-20260924","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-20260924","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/TP.0b013e3181ec7228","article-title":"Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients","volume":"90","author":"Lott","year":"2010","journal-title":"Transplantation"},{"key":"R7-20260924","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2019.09.072","article-title":"Melanoma incidence, stage, and survival after solid organ transplant: a population-based cohort study in Ontario, Canada","volume":"83","author":"Park","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R8-20260924","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur J Immunol"},{"key":"R9-20260924","doi-asserted-by":"crossref","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"R10-20260924","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"R11-20260924","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"R12-20260924","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB\u2013IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"},{"key":"R13-20260924","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R14-20260924","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/jamadermatol.2016.0780","article-title":"Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies","volume":"152","author":"Jacobsen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R15-20260924","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R16-20260924","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R17-20260924","doi-asserted-by":"crossref","first-page":"23247096221121408","DOI":"10.1177\/23247096221121408","article-title":"Cemiplimab for locally advanced cutaneous squamous cell carcinoma: a case series of 3 unique scenarios","volume":"10","author":"Akhtar","year":"2022","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R18-20260924","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity","volume":"103","author":"Akturk","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20260924","first-page":"5908411","article-title":"Plasmapheresis for pembrolizumab-induced hepatitis in a patient with squamous cell carcinoma and prior orthotopic liver transplantation","volume":"2022","author":"Al-Nattah","year":"2022","journal-title":"Case Rep Hepatol"},{"key":"R20-20260924","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transpl"},{"key":"R21-20260924","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1200\/JOP.19.00567","article-title":"Successful administration of cemiplimab to a patient with advanced cutaneous squamous cell carcinoma after renal transplantation","volume":"16","author":"Ali","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"R22-20260924","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CJI.0000000000000514","article-title":"Rapid life-saving response to anti-PD-1 in a solid organ transplant recipient with metastatic cutaneous squamous cell carcinoma: a case report and review","volume":"47","author":"Antonelli","year":"2024","journal-title":"J Immunother"},{"key":"R23-20260924","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.annder.2022.01.003","article-title":"Efficacy of nivolumab in the treatment of metastatic cutaneous squamous cell carcinoma in a kidney-transplant patient with a history of allograft rejection","volume":"149","author":"Bastos","year":"2022","journal-title":"Ann Dermatol Venereol"},{"key":"R24-20260924","doi-asserted-by":"crossref","first-page":"220","DOI":"10.14423\/SMJ.0000000000001508","article-title":"Tri-site Academic Center experience with immunotherapy for metastatic skin cancer in solid organ transplant patients","volume":"116","author":"Berman","year":"2023","journal-title":"South Med J"},{"key":"R25-20260924","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.transproceed.2017.06.007","article-title":"Donor-derived metastatic melanoma and checkpoint inhibition","volume":"49","author":"Boyle","year":"2017","journal-title":"Transpl Proc"},{"key":"R26-20260924","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdcr.2021.05.012","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma","volume":"14","author":"Brumfiel","year":"2021","journal-title":"JAAD Case Rep"},{"key":"R27-20260924","doi-asserted-by":"crossref","first-page":"376","DOI":"10.36849\/JDD.8234","article-title":"Metastatic merkel cell carcinoma after simultaneous pancreas-kidney transplantation: fatal outcomes","volume":"23","author":"Burke","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"R28-20260924","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/0284186X.2020.1747637","article-title":"Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities","volume":"59","author":"Bystrup Boyles","year":"2020","journal-title":"Acta Oncol"},{"key":"R29-20260924","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jdv.17658","article-title":"Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab","volume":"36","author":"Orte Cano","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R30-20260924","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"R31-20260924","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00262-020-02644-2","article-title":"Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy","volume":"69","author":"Danesh","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R32-20260924","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.healun.2020.02.015","article-title":"Immune checkpoint inhibitors in heart or lung transplantation: early results from a registry initiative","volume":"39","author":"Daud","year":"2020","journal-title":"J Heart Lung Transpl"},{"key":"R33-20260924","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/ajt.16589","article-title":"Cytokine storm induced by a PD1 inhibitor in a renal transplant patient","volume":"21","author":"Del Bello","year":"2021","journal-title":"Am J Transpl"},{"key":"R34-20260924","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"R35-20260924","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1097\/TP.0000000000001861","article-title":"Severe allograft rejection and autoimmune hemolytic anemia after anti-PD1 therapy in a kidney transplanted patient","volume":"101","author":"Deltombe","year":"2017","journal-title":"Transplantation"},{"key":"R36-20260924","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/TP.0000000000003292","article-title":"Immune checkpoint inhibitors in Transplantation-A case series and comprehensive review of current knowledge","volume":"105","author":"Delyon","year":"2021","journal-title":"Transplantation"},{"key":"R37-20260924","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mdx281","article-title":"Acute liver graft rejection after ipilimumab therapy","volume":"28","author":"Dueland","year":"2017","journal-title":"Ann Oncol"},{"key":"R38-20260924","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41467-023-37230-4","article-title":"Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy","volume":"14","author":"Dunlap","year":"2023","journal-title":"Nat Commun"},{"key":"R39-20260924","doi-asserted-by":"crossref","first-page":"534","DOI":"10.6002\/ect.2023.0018","article-title":"Successful shrinkage of a giant cutaneous squamous cell carcinoma with immunotherapy in a kidney transplant recipient","volume":"21","author":"Eleftheriadis","year":"2023","journal-title":"Exp Clin Transpl"},{"key":"R40-20260924","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"key":"R41-20260924","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/ced.15018","article-title":"Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus","volume":"47","author":"Gambichler","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"R42-20260924","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/annonc\/mdw293","article-title":"Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient","volume":"27","author":"Gastman","year":"2016","journal-title":"Ann Oncol"},{"key":"R43-20260924","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/jdv.17732","article-title":"Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report","volume":"36","author":"Geidel","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R44-20260924","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12882-018-1003-5","article-title":"PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report","volume":"19","author":"Goldman","year":"2018","journal-title":"BMC Nephrol"},{"key":"R45-20260924","doi-asserted-by":"crossref","first-page":"660795","DOI":"10.3389\/fimmu.2021.660795","article-title":"Case report: single dose Anti-PD1 in a patient with metastatic melanoma and cardiac allograft","volume":"12","author":"Goodman","year":"2021","journal-title":"Front Immunol"},{"key":"R46-20260924","first-page":"137","article-title":"Treatment of unresectable cutaneous squamous cell carcinoma with cemiplimab in a patient on dialysis","volume":"16","author":"Grace de Lima","year":"2023","journal-title":"Case Rep Oncol"},{"key":"R47-20260924","doi-asserted-by":"crossref","first-page":"MMT10","DOI":"10.2217\/mmt-2018-0004","article-title":"Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations","volume":"5","author":"Grant","year":"2018","journal-title":"Melanoma Manag"},{"key":"R48-20260924","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2018.12.027","article-title":"CMV disease and colitis in a kidney transplanted patient under pembrolizumab","volume":"109","author":"Gueguen","year":"2019","journal-title":"Eur J Cancer"},{"key":"R49-20260924","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CMR.0000000000000651","article-title":"The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma","volume":"30","author":"Hanna","year":"2020","journal-title":"Melanoma Res"},{"key":"R50-20260924","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:01:00Z","timestamp":1790226060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005114","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}